Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
September 29, 2026
Endocrinology Strategic Roundup: Beyond Glycemic Control | Aug 25 – Sept 28, 2026
September 25, 2026
Public Health Strategic Roundup: Lifestyle, Risk and Population Health | Aug 21 – Sep 24, 2026
September 23, 2026
Immunology Strategic Roundup: Expansion Meets Safety | Aug 18 – Sept 22, 2026
September 21, 2026
Hematology Strategic Roundup: Efficacy Meets Usability | Aug 14 – Sept 17, 2026
September 17, 2026
Rare Diseases Strategic Roundup: From Approval To Access | Aug 12 – Sep 16, 2026
September 14, 2026
Oncology Strategic Roundup | Aug 07 – Sep 10, 2026
September 11, 2026